Crismon M L
College of Pharmacy, the University of Texas at Austin, Texas 78712, USA.
Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):47-54; discussion 79-82.
Cholinesterase inhibitors are the first agents to be successfully developed specifically for the treatment of cognitive decline associated with Alzheimer's disease. Basic knowledge of their pharmacokinetics is important to their appropriate administration. Their pharmacokinetics help determine the magnitude and duration of their pharmacologic effects, and also the manner in which they affect the degree of cholinesterase inhibition and recovery. The clinical utility of measuring these values in daily practice awaits further research. Drug interactions with cholinesterase inhibitors may occur by pharmacokinetic or pharmacodynamic mechanisms. For the most part, interactions that are mediated by the hepatic cytochrome P-450 system have been inadequately evaluated.
胆碱酯酶抑制剂是首批专门为治疗与阿尔茨海默病相关的认知衰退而成功研发的药物。了解其药代动力学的基本知识对于合理用药很重要。它们的药代动力学有助于确定其药理作用的强度和持续时间，以及它们影响胆碱酯酶抑制程度和恢复的方式。在日常实践中测量这些值的临床实用性有待进一步研究。与胆碱酯酶抑制剂的药物相互作用可能通过药代动力学或药效学机制发生。在很大程度上，由肝细胞色素P-450系统介导的相互作用尚未得到充分评估。
